Show simple item record

dc.contributor.authorde Bruyn, M
dc.contributor.authorWiersma, VR
dc.contributor.authorHelfrich, W
dc.contributor.authorEggleton, P
dc.contributor.authorBremer, E
dc.date.accessioned2015-04-01T11:20:57Z
dc.date.issued2015-02-20
dc.description.abstractCalreticulin is a pleiotropic molecule that normally resides in the lumen of the endoplasmic reticulum (ER). Here, it has various functions, ranging from regulation of calcium homeostasis to ensuring proper protein folding. More recently, calreticulin gained special interest for its extracellular functions, where it has direct immunomodulatory activity. In this respect, calreticulin activates dendritic cells and macrophages. In addition, certain anti-cancer therapies induce the translocation of calreticulin from the ER to the cell surface of dying cancer cells, where calreticulin dictates the immunogenicity of these cells. Interestingly, treatment with tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) also induces membrane calreticulin exposure on cancer cells. As shown here, calreticulin directly interacts with TRAIL and its receptor-signaling complex, as well as with other TNF family members. Of note, TRAIL is a well known immunomodulatory molecule, and is expressed on the surface of natural killer T-cells. Therefore, calreticulin may have an as yet unrecognized wide(r) impact on immunity, with the TNF-ligand family modulating virtually all aspects of the immune response.en_GB
dc.description.sponsorshipDutch Cancer Societyen_GB
dc.description.sponsorshipNetherlands Organization for Scientific Researchen_GB
dc.description.sponsorshipEuropean Communities Seventh Framework Programme (FP7/2007-2013)en_GB
dc.identifier.citationFrontiers in Oncology, 2015, Vol. 5, Issue 35en_GB
dc.identifier.doi10.3389/fonc.2015.00035
dc.identifier.grantnumberRUG 2009-4355 (EB), RUG2009-4542, RUG2011-5206, RUG2012-5541, RUG2013-6209en_GB
dc.identifier.grantnumber215009 RedCat (PE)en_GB
dc.identifier.urihttp://hdl.handle.net/10871/16649
dc.language.isoenen_GB
dc.publisherFrontiersen_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/25750898en_GB
dc.rightsThis Document is Protected by copyright and was first published by Frontiers. All rights reserved. it is reproduced with permission. © 2015 de Bruyn, Wiersma, Helfrich, Eggleton and Bremer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_GB
dc.subjectTNFen_GB
dc.subjectcalreticulinen_GB
dc.subjectcomplex formationen_GB
dc.subjectimmunogenic cell deathen_GB
dc.subjectimmunomodulationen_GB
dc.subjecttumor necrosis factor related apoptosis inducing liganden_GB
dc.titleThe ever-expanding immunomodulatory role of calreticulin in cancer immunity.en_GB
dc.typeArticleen_GB
dc.date.available2015-04-01T11:20:57Z
dc.identifier.issn2234-943X
exeter.place-of-publicationSwitzerland
dc.descriptionThis is a freely-available open access publication. Please cite the published version which is available via the DOI link in this record.en_GB
dc.identifier.journalFrontiers in Oncologyen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record